Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity.
Carretero-Gómez J, Carrasco-Sánchez FJ, Fernández-Rodríguez JM, Casado-Escribano P, Miramontes-González JP, Seguí-Ripoll JM, Ena J, Arévalo-Lorido JC; Diabetes, Obesity, and Nutrition Working Group of the Spanish Society of Internal Medicine (SEMI).
Carretero-Gómez J, et al. Among authors: ena j.
Rev Clin Esp (Barc). 2023 Mar;223(3):134-143. doi: 10.1016/j.rceng.2022.12.001. Epub 2022 Dec 19.
Rev Clin Esp (Barc). 2023.
PMID: 36549643